Activity Report and Latest Information
- HOME
- Activity Report and Latest Information
- Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan (Paper)
Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan (Paper)
Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan by Dr. Tomoyuki Hayashi has been published on Scientific Reports.
HCV treatment became cost-effective after 9 years of starting treatment. However, if the price of DAAs is reduced by 55?85%, HCV treatment would be cost-saving within a 5 to 20-year time horizon, which should serve to increase the uptake of DAA-based HCV treatment.
HCV treatment became cost-effective after 9 years of starting treatment. However, if the price of DAAs is reduced by 55?85%, HCV treatment would be cost-saving within a 5 to 20-year time horizon, which should serve to increase the uptake of DAA-based HCV treatment.
